Ketamine decreases resting state functional connectivity between networks via 
the dorsal nexus: implications for major depression

Scheidegger, M; Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Seifritz, E; Henning, A

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

このアイテムの新しいバージョンが利用可能です:
https://pure.mpg.de/pubman/item/item_1787651_2

詳細要約

公開

講演

Ketamine decreases resting state functional connectivity between networks via the dorsal nexus: implications for major depression

MPS-Authors

/persons/resource/persons84402

Henning, A
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Scheidegger, M., Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Seifritz, E., & Henning, A. (2012). Ketamine decreases resting state functional connectivity between networks via the dorsal nexus: implications for major depression. Talk presented at 20th Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine (ISMRM 2012). Melbourne, Australia.

引用: https://hdl.handle.net/11858/00-001M-0000-0013-B758-A

要旨

Using resting state fMRI (rsfMRI), the „dorsal nexus“ (DN) was recently identified as a dorsomedial prefrontal cortex region showing increased depression-associated fMRI connectivity with portions of the cognitive control (CCN), the default mode (DMN), and the affective (AN) network. In this double-blind, randomized, placebo-controlled, crossover study we report decreased connectivity of the sgACC (AN) and PCC (DMN) via the DN 24 hours following the administration of an antidepressant dose of ketamine. We conclude that reducing the hyperconnectivity via the DN may play a critical role in reducing depressive symptomatology and thus represent a systems level mechanism of antidepressant treatment response.